Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes
Diabetes Research and Clinical Practice, Volume 76, No. 2, Year 2007
Notification
URL copied to clipboard!
Description
Introduction: Insulin glulisine (glulisine) was evaluated versus regular human insulin (RHI) in Type 2 diabetes (T2DM) patients. Methods: Patients previously on >6 months' continuous insulin treatment aged ≥18 years in a randomized, multinational, controlled, open-label, parallel group, 26-week study received twice-daily NPH insulin and either glulisine (0-15 min before breakfast and dinner; n = 448) or RHI (30-45 min before breakfast and dinner; n = 442) at least twice daily. Results: Mean baseline characteristics were similar between groups. There were no differences in baseline to endpoint HbA1c reductions (glulisine: -0.32%; RHI: -0.35%; p = 0.5726), and the non-inferiority of glulisine versus RHI was demonstrated (difference in adjusted mean change 0.03%; 95% CI: -0.07, 0.13). Postprandially, glulisine lowered plasma glucose significantly more versus RHI at 2 h (14.14 mmol/L versus 15.28 mmol/L; p = 0.0025) and excursions at 1 h (3.99 versus 4.59; p = 0.0151) and 2 h (4.87 versus 6.03; p = 0.0002). No between-group differences occurred in the frequencies and monthly rates of all symptomatic hypoglycaemia; nocturnal hypoglycaemia from Month 4 to treatment end was less frequent with glulisine versus RHI (9.1% versus 14.5%; p = 0.029). Conclusion: Glulisine was non-inferior to RHI in reducing HbA1c in T2DM. Glulisine demonstrated superior postprandial glucose control and was associated with fewer nocturnal hypoglycaemic episodes, indicating clinical benefits. © 2006 Elsevier Ireland Ltd. All rights reserved.
Authors & Co-Authors
Rayman, Gerry A.
United Kingdom, Colchester
East Suffolk and North Essex Nhs Foundation Trust
Profozić, Velimir
Croatia, Zagreb
University of Zagreb School of Medicine
Middle, Michelle Vivienne
South Africa, George
South Africa Clinical Trials Ltd.
Statistics
Citations: 40
Authors: 3
Affiliations: 3
Identifiers
Doi:
10.1016/j.diabres.2006.09.006
ISSN:
01688227
Research Areas
Noncommunicable Diseases